Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses (Q41068583)

26 September 2017

Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses (English)

1 reference

26 September 2017

1 reference

1 reference

1 reference

Nan Meng

1

1 reference

26 September 2017

Xiao Gao

2

1 reference

26 September 2017

Wei Yan

3

1 reference

26 September 2017

Mi Wang

4

1 reference

26 September 2017

Ping Liu

5

1 reference

26 September 2017

Xiao-dan Lu

6

1 reference

26 September 2017

Shu-juan Zhang

7

1 reference

26 September 2017

Ya-qi Lu

8

1 reference

26 September 2017

Wang-xian Tang

9

1 reference

26 September 2017

16 April 2015

1 reference

Journal of Huazhong University of Science and Technology. Medical Sciences

26 September 2017

1 reference

26 September 2017

35

1 reference

26 September 2017

230-234

1 reference

26 September 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s11596-015-1416-3

26 September 2017

0 references

cites work

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Prevalence of hepatitis B in the southeast of China: a population-based study with a large sample size

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Epidemiology and natural history of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Effect and Predictive Elements for 52 Weeks' Telbivudine Treatment on Naïve HBeAg positive Chronic Hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Hepatitis B virus (HBV) induces the expression of interleukin-8 that in turn reduces HBV sensitivity to interferon-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Immunology of hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Global control of hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Recovery of functional cytotoxic T lymphocytes during lamivudine therapy by acquiring multi-specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Telbivudine versus lamivudine in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Assessment of prognosis in alcoholic liver disease: can serum hyaluronate replace liver biopsy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Prothrombin index is an indirect marker of severe liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Noninvasive diagnosis of hepatic fibrosis or cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Therapy of chronic hepatitis B: focus on telbivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Innate and adaptive immune responses in hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Effects of telbivudine treatment on the circulating CD4⁺ T-cell subpopulations in chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Natural killer cells are characterized by the concomitantly increased interferon-γ and cytotoxicity in acute resolved hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Regulatory T cells and viral liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Specialization in tolerance: innate CD(4+)CD(25+) versus acquired TR1 and TH3 regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-015-1416-3

Serum hyaluronan--a non-invasive test for diagnosing liver cirrhosis

21 January 2018

1 reference

12 December 2020

Prothrombin index decrease: a useful and reliable marker of extensive fibrosis?

1 reference

12 December 2020

1 reference

12 December 2020

Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver

1 reference

12 December 2020

Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C

1 reference

12 December 2020

On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future.

1 reference

12 December 2020

Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B

1 reference

12 December 2020

Biopsy diagnosis of cirrhosis: blind percutaneous versus guided direct vision techniques—a review

1 reference

12 December 2020

HBX-mediated migration of HBV-replicating HepG2 cells: insights on development of hepatocellular carcinoma

1 reference

12 December 2020

Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies

1 reference

12 December 2020

The regulation of inflammation by interferons and their STATs

1 reference

12 December 2020

Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil

1 reference

12 December 2020

10.1007/S11596-015-1416-3

Identifiers

DOI

1 reference

26 September 2017

1 reference